Chemours (NYSE:CC) Given New $25.00 Price Target at BMO Capital Markets

Chemours (NYSE:CC) had its price target raised by stock analysts at BMO Capital Markets from $23.00 to $25.00 in a research note issued to investors on Thursday, Stock Target Advisor reports. The brokerage presently has an “outperform” rating on the specialty chemicals company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 26.97% from the company’s previous close.

Several other brokerages have also recently commented on CC. ValuEngine cut Chemours from a “hold” rating to a “sell” rating in a research report on Friday, November 1st. Susquehanna Bancshares raised Chemours from a “neutral” rating to a “positive” rating and reduced their target price for the stock from $37.00 to $18.00 in a research report on Tuesday, August 20th. TheStreet cut Chemours from a “b-” rating to a “c+” rating in a research report on Friday, August 9th. Royal Bank of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $32.00 to $16.00 in a research report on Friday, August 9th. Finally, Cfra raised Chemours from a “hold” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $27.14.

CC stock traded up $0.04 during midday trading on Thursday, hitting $19.69. The stock had a trading volume of 1,702,921 shares, compared to its average volume of 2,583,418. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of 3.47, a P/E/G ratio of 0.51 and a beta of 2.57. Chemours has a 52 week low of $11.71 and a 52 week high of $41.60. The stock has a 50-day simple moving average of $15.60 and a 200 day simple moving average of $19.81. The company has a current ratio of 1.72, a quick ratio of 1.09 and a debt-to-equity ratio of 5.05.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.56 by $0.03. The firm had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Chemours had a return on equity of 58.38% and a net margin of 7.24%. Chemours’s quarterly revenue was down 14.6% compared to the same quarter last year. During the same period last year, the business earned $1.49 earnings per share. On average, equities analysts forecast that Chemours will post 2.44 EPS for the current year.

In related news, COO Mark Newman acquired 20,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was purchased at an average cost of $16.42 per share, for a total transaction of $328,400.00. Following the completion of the purchase, the chief operating officer now directly owns 114,261 shares of the company’s stock, valued at approximately $1,876,165.62. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.34% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in CC. AMG National Trust Bank increased its stake in shares of Chemours by 2.3% in the third quarter. AMG National Trust Bank now owns 32,250 shares of the specialty chemicals company’s stock valued at $482,000 after buying an additional 712 shares in the last quarter. Investors Research Corp increased its stake in shares of Chemours by 148.1% in the second quarter. Investors Research Corp now owns 1,206 shares of the specialty chemicals company’s stock valued at $29,000 after buying an additional 720 shares in the last quarter. Cerebellum GP LLC increased its stake in shares of Chemours by 107.8% in the third quarter. Cerebellum GP LLC now owns 1,490 shares of the specialty chemicals company’s stock valued at $75,000 after buying an additional 773 shares in the last quarter. Brandywine Oak Private Wealth LLC increased its stake in shares of Chemours by 2.6% in the third quarter. Brandywine Oak Private Wealth LLC now owns 33,820 shares of the specialty chemicals company’s stock valued at $505,000 after buying an additional 844 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Chemours by 7.5% in the second quarter. KBC Group NV now owns 12,837 shares of the specialty chemicals company’s stock valued at $308,000 after buying an additional 894 shares in the last quarter. Hedge funds and other institutional investors own 79.88% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: What is an economic bubble?

Stock Target Advisor

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.